NCT05857384View on ClinicalTrials.gov

Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs

PHASE1CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

September 8, 2023

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2024

Conditions
Obstructive Sleep Apnea
Interventions
DRUG

IHL42X

IHL-42X consists of acetazolamide and dronabinol.

DRUG

Acetazolamide 250 MG

A solid tablet containing 250 mg acetazolamide

DRUG

Dronabinol 2.5 MG

A soft gelatin capsules containing 2.5mg dronabinol

Trial Locations (4)

3004

Nucleus Network Pty Ltd [Commercial Road], Melbourne

Nucleus Network Pty Ltd, Melbourne

3220

Nucleus Network Pty Ltd, Geelong

5000

CMAX, Adelaide

Sponsors
All Listed Sponsors
lead

Incannex Healthcare Ltd

INDUSTRY

NCT05857384 - Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs | Biotech Hunter | Biotech Hunter